An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

Brief description of study

The purpose of the study is to determine if durvalumab works and is safe for the treatment of cancer. This study will enroll patients who are currently receiving durvalumab or have previously received durvalumab as monotherapy or in combination with other drugs in an eligible AstraZeneca/MedImmune-sponsored study. We want to know the long term safety of durvalumab and to provide continued treatment or retreatment with durvalumab to eligible patients.


Clinical Study Identifier: s19-01107
ClinicalTrials.gov Identifier: NCT04078152


If you are registered as a volunteer, please login to the dashboard to send referrals.